CO-STAR
Research type
Research Study
Full title
A randomised feasibility study COmparing Urolift and Standard Transurethral resection of prostate Ahead of Radiotherapy in men with urinary symptoms secondary to prostate enlargement
IRAS ID
280225
Contact name
Kathie Wong
Contact email
Sponsor organisation
The Royal Marsden NHS Foundation Trust
Clinicaltrials.gov Identifier
Duration of Study in the UK
2 years, 0 months, 0 days
Research summary
Men with prostate cancer undergoing radiotherapy often have co-existing lower urinary tract symptoms (LUTS) secondary to prostate hyperplasia. These symptoms can preclude radiotherapy treatment or exacerbate complications during and post treatment. Currently, patients are formally assessed in a dedicated LUTS clinic and patients with symptoms may be offered further LUTS treatment including lifestyle advice, medication and surgery. Patients with the most severe symptoms are offered a transurethral resection of prostate (TURP). This is an operation which involves a general / spinal anaesthetic and average length of stay of two days. There are side effects associated with surgery and radiotherapy combined needs to be postponed 4-6 weeks to allow patients to recover from surgery. \n\nUroLift offers a minimally invasive alternative to TURP which can be performed as a day case with a 0.2 day length of stay. It is a NICE approved product widely accepted as treatment for Benign Prostate Hpyerplasia (BPH). We aim to evaluate the clinical outcomes, safety, feasibility and tolerability of Urolift as a treatment for LUTS for men undergoing prostate radiotherapy.
REC name
South West - Frenchay Research Ethics Committee
REC reference
22/SW/0137
Date of REC Opinion
20 Dec 2022
REC opinion
Further Information Favourable Opinion